PortalPublikationenReduced intensity conditioning regimens including alkylating...

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

Standard

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. / Andersen, Niels Smedegaard; Bornhäuser, Martin; Gramatzki, Martin; Dreger, Peter; Vitek, Antonin; Karas, Michal; Michallet, Mauricette; Moreno, Carol; van Gelder, Michel; Henseler, Anja; de Wreede, Liesbeth C; Schönland, Stefan; Kröger, Nicolaus; Schetelig, Johannes; CLL subcommittee, Chronic Malignancies Working Party.

in: J CANCER RES CLIN, Jahrgang 145, Nr. 11, 11.2019, S. 2823-2834.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Andersen, NS, Bornhäuser, M, Gramatzki, M, Dreger, P, Vitek, A, Karas, M, Michallet, M, Moreno, C, van Gelder, M, Henseler, A, de Wreede, LC, Schönland, S, Kröger, N, Schetelig, J & CLL subcommittee, Chronic Malignancies Working Party 2019, 'Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning', J CANCER RES CLIN, Jg. 145, Nr. 11, S. 2823-2834. https://doi.org/10.1007/s00432-019-03014-x

APA

Andersen, N. S., Bornhäuser, M., Gramatzki, M., Dreger, P., Vitek, A., Karas, M., Michallet, M., Moreno, C., van Gelder, M., Henseler, A., de Wreede, L. C., Schönland, S., Kröger, N., Schetelig, J., & CLL subcommittee, Chronic Malignancies Working Party (2019). Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. J CANCER RES CLIN, 145(11), 2823-2834. https://doi.org/10.1007/s00432-019-03014-x

Vancouver

Andersen NS, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M et al. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. J CANCER RES CLIN. 2019 Nov;145(11):2823-2834. https://doi.org/10.1007/s00432-019-03014-x

Bibtex

@article{d7ab4c45e4cb423986aeb05efdfd9ae7,
title = "Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning",
abstract = "PURPOSE: The optimal dose intensity for conditioning prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) is unknown.METHODS: We retrospectively compared outcomes of patients who received a first alloHCST after non-myeloablative (NMA) and reduced intensity conditioning (RIC). Data of 432 patients with a median age of 55 years were included, of which 86 patients underwent NMA and 346 RIC.RESULTS: The median follow-up after alloHSCT was 4.3 years. Compared to the RIC group, more NMA patients had purine-analog-sensitive disease, were in complete remission and received matched related donor transplantation. After RIC, the probabilities for 5-year OS, EFS, CIR, and NRM were 46%, 38%, 28%, and 35% and after NMA the respective probabilities were 52%, 43%, 25%, and 32%. In multivariate analysis, remission status prior to conditioning but not RIC versus NMA conditioning had a significant impact on CIR, EFS, and OS.CONCLUSION: Presumed higher anti-leukemic activity of RIC versus NMA conditioning did not translate into better outcomes after alloHSCT, but better remission status prior to conditioning did. Effective pathway inhibitor-based salvage therapies combined with NMA conditioning might thus represent the most attractive contemporary approach for alloHSCT for patients with CLL.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Busulfan/administration & dosage, Combined Modality Therapy, Cyclophosphamide/administration & dosage, Female, Follow-Up Studies, Graft vs Host Disease/epidemiology, Hematopoietic Stem Cell Transplantation/mortality, Humans, Incidence, Leukemia, Lymphocytic, Chronic, B-Cell/mortality, Male, Melphalan/administration & dosage, Middle Aged, Prognosis, Remission Induction, Retrospective Studies, Survival Rate, Transplantation Conditioning/mortality, Transplantation, Homologous, Young Adult",
author = "Andersen, {Niels Smedegaard} and Martin Bornh{\"a}user and Martin Gramatzki and Peter Dreger and Antonin Vitek and Michal Karas and Mauricette Michallet and Carol Moreno and {van Gelder}, Michel and Anja Henseler and {de Wreede}, {Liesbeth C} and Stefan Sch{\"o}nland and Nicolaus Kr{\"o}ger and Johannes Schetelig and {CLL subcommittee, Chronic Malignancies Working Party}",
year = "2019",
month = nov,
doi = "10.1007/s00432-019-03014-x",
language = "English",
volume = "145",
pages = "2823--2834",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "11",

}

RIS

TY - JOUR

T1 - Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

AU - Andersen, Niels Smedegaard

AU - Bornhäuser, Martin

AU - Gramatzki, Martin

AU - Dreger, Peter

AU - Vitek, Antonin

AU - Karas, Michal

AU - Michallet, Mauricette

AU - Moreno, Carol

AU - van Gelder, Michel

AU - Henseler, Anja

AU - de Wreede, Liesbeth C

AU - Schönland, Stefan

AU - Kröger, Nicolaus

AU - Schetelig, Johannes

AU - CLL subcommittee, Chronic Malignancies Working Party

PY - 2019/11

Y1 - 2019/11

N2 - PURPOSE: The optimal dose intensity for conditioning prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) is unknown.METHODS: We retrospectively compared outcomes of patients who received a first alloHCST after non-myeloablative (NMA) and reduced intensity conditioning (RIC). Data of 432 patients with a median age of 55 years were included, of which 86 patients underwent NMA and 346 RIC.RESULTS: The median follow-up after alloHSCT was 4.3 years. Compared to the RIC group, more NMA patients had purine-analog-sensitive disease, were in complete remission and received matched related donor transplantation. After RIC, the probabilities for 5-year OS, EFS, CIR, and NRM were 46%, 38%, 28%, and 35% and after NMA the respective probabilities were 52%, 43%, 25%, and 32%. In multivariate analysis, remission status prior to conditioning but not RIC versus NMA conditioning had a significant impact on CIR, EFS, and OS.CONCLUSION: Presumed higher anti-leukemic activity of RIC versus NMA conditioning did not translate into better outcomes after alloHSCT, but better remission status prior to conditioning did. Effective pathway inhibitor-based salvage therapies combined with NMA conditioning might thus represent the most attractive contemporary approach for alloHSCT for patients with CLL.

AB - PURPOSE: The optimal dose intensity for conditioning prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) is unknown.METHODS: We retrospectively compared outcomes of patients who received a first alloHCST after non-myeloablative (NMA) and reduced intensity conditioning (RIC). Data of 432 patients with a median age of 55 years were included, of which 86 patients underwent NMA and 346 RIC.RESULTS: The median follow-up after alloHSCT was 4.3 years. Compared to the RIC group, more NMA patients had purine-analog-sensitive disease, were in complete remission and received matched related donor transplantation. After RIC, the probabilities for 5-year OS, EFS, CIR, and NRM were 46%, 38%, 28%, and 35% and after NMA the respective probabilities were 52%, 43%, 25%, and 32%. In multivariate analysis, remission status prior to conditioning but not RIC versus NMA conditioning had a significant impact on CIR, EFS, and OS.CONCLUSION: Presumed higher anti-leukemic activity of RIC versus NMA conditioning did not translate into better outcomes after alloHSCT, but better remission status prior to conditioning did. Effective pathway inhibitor-based salvage therapies combined with NMA conditioning might thus represent the most attractive contemporary approach for alloHSCT for patients with CLL.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Busulfan/administration & dosage

KW - Combined Modality Therapy

KW - Cyclophosphamide/administration & dosage

KW - Female

KW - Follow-Up Studies

KW - Graft vs Host Disease/epidemiology

KW - Hematopoietic Stem Cell Transplantation/mortality

KW - Humans

KW - Incidence

KW - Leukemia, Lymphocytic, Chronic, B-Cell/mortality

KW - Male

KW - Melphalan/administration & dosage

KW - Middle Aged

KW - Prognosis

KW - Remission Induction

KW - Retrospective Studies

KW - Survival Rate

KW - Transplantation Conditioning/mortality

KW - Transplantation, Homologous

KW - Young Adult

U2 - 10.1007/s00432-019-03014-x

DO - 10.1007/s00432-019-03014-x

M3 - SCORING: Journal article

C2 - 31468122

VL - 145

SP - 2823

EP - 2834

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 11

ER -